EUVIMEDEUVIMED entdecken
Crossref

Ratio‐Tunable Dual‐Peptide and Ultrasound‐Assisted Nanoplatform for Enhancing Personalized Antitumor Immunotherapy

Weifeng Shi, Heqi Gao, Jingtian Zhang iD, Yuansheng Duan, Chao Jing, Kai Yue, Jiayan Cao, Dan Ding iD, Yansheng Wu, Jianwu Tian, Xudong Wang

Advanced Materials · 2026

DOI: 10.1002/adma.202516433 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, 2026. Verfasst von Weifeng Shi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Oncology, Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Basic and Translational Medicine on H…. Hauptthemen laut MEDLINE: Immunotherapy, Peptides, Nanoparticles, Ultrasonic Waves. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Peak Discipline Support Program of the 14th Five-Year Plan of Tianjin Medical University Cancer Institute & Hospital, National Key R&D Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint‐based immunotherapy has become a central strategy for treating solid tumors by restoring endogenous antitumor immunity. However, clinical responses remain limited and highly variable across patients and tumor types because co‐existing inhibitory pathways are engaged to different extents, while current therapies generally rely on fixed targeting architectures and are not designed to accommodate patient specific checkpoint dependence. Here, we developed ratio tunable bispecific nanoparticles (BiNPs) for personalized immune checkpoint‐based immunotherapy by co‐assembling an aggregation induced emission sonosensitizer core with two β‐sheet self‐assembling peptides, Pep@CD47 and Pep@PD‐L1, enabling programmable control of peptide stoichiometry. BiNPs promote lysosomal internalization and degradation of CD47 and PD‐L1 through a lysosome targeting chimera inspired process, and ultrasound‐activated sonodynamic therapy generates reactive oxygen species to induce immunogenic cell death with calreticulin exposure and ATP and HMGB1 release. In syngeneic SCC‐7 tumor models, ultrasound‐activated BiNPs with a selected peptide ratio enhance dendritic cell maturation, shift macrophages toward an M1‐like phenotype, increase CD8 + T cell infiltration, and suppress primary and distant tumors with favorable biosafety. Ex vivo screening of freshly resected HNSCC specimens identifies distinct optimal Pep@CD47: Pep@PD‐L1 ratios among patients, demonstrating that BiNPs offer a personalized approach for effective immunotherapy across heterogeneous solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyPeptidesNanoparticlesUltrasonic WavesPrecision MedicineHumansAnimalsCD47 AntigenCell Line, TumorB7-H1 AntigenMiceUltrasonic Therapy

Stichwörter der Autor:innen

aggregation‐induced emissioncancer immunotherapyimmunogenic cell deathself‐assembling peptidesonosensitizer

Substanzen

PeptidesCD47 AntigenB7-H1 Antigen

Autor:innen und Institutionen

  • Department of Head and Neck Oncology, Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Basic and Translational Medicine on Head & Neck Cancer, Tianjin, National Clinical Research Center for Canc…
  • College of Chemistry, Engineering Research Center of Energy Storage and Devices, Xi'an Key Laboratory of Sustainable Polymers, Ministry of Education, Xi'an Jiaotong University, Xi'an, Shaanxi, P. R. China.
  • Frontiers Science Center for New Organic Matter, State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences and Academy for Advanced Interdisciplinary Studies, Nankai University, Tianjin, P. R. China.
  • Nankai International Advanced Research Institute (Shenzhen Futian), Nankai University, Shenzhen, P. R. China.

ORCID-Profile: Jingtian Zhang, Dan Ding

Förderung

  • National Natural Science Foundation of China
  • Peak Discipline Support Program of the 14th Five-Year Plan of Tianjin Medical University Cancer Institute & Hospital
  • National Key R&D Program of China
  • National Key Research and Development Program of China

Zitieren

APA

Shi, W., Gao, H., Zhang, J., Duan, Y., Jing, C., Yue, K., Cao, J., Ding, D., Wu, Y., Tian, J., & Wang, X. (2026). Ratio‐Tunable Dual‐Peptide and Ultrasound‐Assisted Nanoplatform for Enhancing Personalized Antitumor Immunotherapy. Advanced Materials. https://doi.org/10.1002/adma.202516433

Vancouver

Shi W, Gao H, Zhang J, Duan Y, Jing C, Yue K, et al. Ratio‐Tunable Dual‐Peptide and Ultrasound‐Assisted Nanoplatform for Enhancing Personalized Antitumor Immunotherapy. Advanced Materials. 2026. doi:10.1002/adma.202516433

BibTeX
@article{Shi2026,
  author = {Shi, Weifeng and Gao, Heqi and Zhang, Jingtian and Duan, Yuansheng and Jing, Chao and Yue, Kai and Cao, Jiayan and Ding, Dan and Wu, Yansheng and Tian, Jianwu and Wang, Xudong},
  title = {Ratio‐Tunable Dual‐Peptide and Ultrasound‐Assisted Nanoplatform for Enhancing Personalized Antitumor Immunotherapy},
  journal = {Advanced Materials},
  year = {2026},
  doi = {10.1002/adma.202516433}
}
Kostenlos starten →